P3 Health Partners sees FY25 revenue $1.35B-$1.5B, consensus $1.43B
FY25 Adjusted EBITDA Forecast: Sese's adjusted EBITDA for FY25 is projected to range between $69 million and $39 million.
Data Training Cutoff: The information provided is based on data available up to October 2023.
Trade with 70% Backtested Accuracy
Analyst Views on PIII
About PIII
About the author
P3 Health Partners Forms Joint Venture with Commonwealth to Expand Value-Based Care
- Joint Venture Formation: P3 Health Partners and Commonwealth Primary Care ACO have established a Joint Venture Management Services Organization aimed at expanding value-based care support across Arizona, California, Nevada, Oregon, and North Carolina, enhancing service capabilities for primary care physicians.
- Market Expansion: This partnership expands P3's footprint into Maricopa County, Arizona, further solidifying its position in a key growth market, which is expected to drive business growth in the region.
- Operational Efficiency Improvement: The joint venture combines P3's strengths in Medicare Advantage and ACO with Commonwealth's ACO REACH program to create a unified operational platform, thereby enhancing performance and efficiency in healthcare delivery.
- Physician Support Enhancement: The joint venture will strengthen support for independent primary care physicians by sharing operations and best practices, ensuring they can thrive and deliver exceptional care in a value-based environment.
Projected Target Price for ONEQ Analyst: $104
ETF Performance Analysis: The Fidelity Nasdaq Composite Index ETF (ONEQ) has an implied analyst target price of $103.84, indicating a potential upside of 10.75% from its current trading price of $93.76.
Notable Holdings: Key underlying holdings with significant upside potential include KODIAK ROBOTICS INC (KDK), Red Cat Holdings Inc (RCAT), and P3 Health Partners Inc (PIII), with expected price increases of 96.58%, 62.44%, and 58.15% respectively.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they are based on outdated information.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analysts' targets in light of recent company and industry developments.
